Stereotactic and functional neurosurgery · 2026
Radiosurgical Irradiation of Spinal Nerve Roots for the Management of Spasticity: A Systematic Review.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Izhar Muhammad, Hori Yusuke S, Kattaa Ahed H, Park David J, Chang Steven D
Аннотация
INTRODUCTION: Spasticity is a common and debilitating sensorimotor disorder resulting from injury to the brain or spinal cord. Conventional treatments, including oral antispasmodic agents, botulinum injections, intrathecal baclofen (ITB) pumps, and selective dorsal rhizotomy, are often limited by side effects, invasiveness, and/or inconsistent outcomes. Stereotactic radiosurgery (SRS), a noninvasive image-guided technique traditionally used in oncology and functional neurosurgery, could emerge as a promising alternative for refractory spasticity. The objective of the manuscript was to review the clinical application, safety, and preliminary efficacy of SRS in managing spasticity.
METHODS: A systematic literature search was conducted following PRISMA guidelines. Studies were included if they reported spasticity as a primary condition and used SRS as a therapeutic modality. Data on patient characteristics, treatment parameters, outcomes, including Modified Ashworth Scale (MAS) scores and Visual Analog Scale (VAS) pain scores, and adverse events were extracted and analyzed.
RESULTS: Three clinical studies involving a total of 7 patients were identified. SRS was delivered to the affected spinal nerve roots at a prescription dose ranging from 45 to 60 Gy. Mean MAS scores improved from 3.66 to 1.5, and mean VAS pain scores decreased from 7.33 to 1.6 over 24 months of follow-up. No major adverse events were reported. Transient side effects, such as reduced trunk control, occurred in 1 patient. Treatment response varied in onset and duration across cases.
CONCLUSION: Early evidence suggests that SRS is a feasible approach for the management of spasticity. However, larger prospective studies with longer follow-up are warranted to determine optimal patient selection, dose parameters, and long-term outcomes, including quality of life and potential radiation-related effects.
METHODS: A systematic literature search was conducted following PRISMA guidelines. Studies were included if they reported spasticity as a primary condition and used SRS as a therapeutic modality. Data on patient characteristics, treatment parameters, outcomes, including Modified Ashworth Scale (MAS) scores and Visual Analog Scale (VAS) pain scores, and adverse events were extracted and analyzed.
RESULTS: Three clinical studies involving a total of 7 patients were identified. SRS was delivered to the affected spinal nerve roots at a prescription dose ranging from 45 to 60 Gy. Mean MAS scores improved from 3.66 to 1.5, and mean VAS pain scores decreased from 7.33 to 1.6 over 24 months of follow-up. No major adverse events were reported. Transient side effects, such as reduced trunk control, occurred in 1 patient. Treatment response varied in onset and duration across cases.
CONCLUSION: Early evidence suggests that SRS is a feasible approach for the management of spasticity. However, larger prospective studies with longer follow-up are warranted to determine optimal patient selection, dose parameters, and long-term outcomes, including quality of life and potential radiation-related effects.